Related Experiment Videos
[Azithromycin and Mycobacterium avium infection]
1Service des Maladies Infectieuses et Tropicales, Hôpital Raymond-Poincaré, Garches, France.
Pathologie-Biologie
|June 1, 1995
Summary
Azithromycin effectively treats Mycobacterium avium infections in AIDS patients, showing high intracellular activity. Ongoing research aims to optimize dosage and combination therapies for improved outcomes and prophylaxis.
Area of Science:
- Infectious Diseases
- Pharmacology
- Immunology
Background:
- Mycobacterium avium infection is a common AIDS complication, often resistant to standard treatments.
- Macrolides like azithromycin offer improved efficacy against M. avium.
Purpose of the Study:
- To evaluate the efficacy of azithromycin against Mycobacterium avium infections.
- To explore azithromycin's role in treatment and prophylaxis for AIDS patients.
Main Methods:
- In vitro susceptibility testing (MICs) and macrophage infection models.
- Murine experimental infection models.
- Clinical studies in AIDS patients and ongoing trials for dosing, combinations, and prophylaxis.
Main Results:
- Azithromycin demonstrates bactericidal activity against M. avium in vitro.
- High intracellular concentrations of azithromycin are achieved, exceeding MIC values.
- Clinical studies confirm azithromycin's activity in disseminated M. avium infections at 600 mg/d.
Conclusions:
- Azithromycin is a valuable therapeutic option for Mycobacterium avium infections in AIDS.
- Further studies are needed to establish optimal dosing, combination therapies, and prophylactic use.